<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976443</url>
  </required_header>
  <id_info>
    <org_study_id>09-000002</org_study_id>
    <nct_id>NCT00976443</nct_id>
  </id_info>
  <brief_title>Effects of Gastric Antral Botulinum Toxin Injections in Obese Subjects</brief_title>
  <official_title>Physiologic Effects of High-Dose Gastric Antral Botulinum Toxin Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is an important public health problem in the United States. The investigators
      hypothesize that stomach injections of botulinum toxin A (BTA), delivered through an
      endoscope using endoscopic ultrasound (EUS), may cause delayed gastric emptying, satiation,
      and reduction in body weight. This protocol is designed to study the effects and safety of
      gastric BTA injections. Subjects are randomized to receive placebo or one of two different
      doses of BTA injected into the stomach during one endoscopy, performed via the mouth. Gastric
      emptying, satiation, symptoms, psychological dimensions of eating behavior, and caloric
      intake are recorded before and after injections, and subjects are seen in follow-up for 24
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Additional information regarding study interventions can be obtained by contacting study
      staff.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight between baseline and 16 weeks after BTA injection.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BMI and waist circumference</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gastric emptying T½</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nutrient drink test maximum tolerated volume (MTV)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gastrointestinal symptoms over time</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gastric injections of normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTA 100 U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gastric injections of botulinum toxin A, 100 Units</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTA 300 U</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BTA 300 U, gastric injections under EUS guidance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTA</intervention_name>
    <description>BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum</description>
    <arm_group_label>BTA 100 U</arm_group_label>
    <arm_group_label>BTA 300 U</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (normal saline)</intervention_name>
    <description>Placebo (normal saline), gastric injections of normal saline</description>
    <arm_group_label>Placebo (normal saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years and ≤ 60 years

          -  BMI ≥ 35 kg /m²

          -  No history of diabetes, gastric or small bowel surgery, known gastroparesis, prior
             peptic ulcer, esophagitis, or gastrointestinal stricture.

          -  Not pregnant or nursing. Women of childbearing potential must have a negative urine
             pregnancy test within 48 hours prior to each gastric emptying study, and the Botox
             injection procedure.

        Exclusion Criteria:

          -  Unable or unwilling to provide written informed consent

          -  ASA Class III or higher

          -  Chronic upper abdominal pain, nausea, or vomiting

          -  Allergy to botulinum toxin

          -  Delayed gastric emptying (abnormal T ½) on baseline scintigraphic gastric emptying
             test

          -  Active esophageal, gastric, or duodenal ulceration at time of diagnostic EGD

          -  Allergic to both penicillins AND quinolones

          -  Subject has taken warfarin (Coumadin) or clopidogrel (Plavix) in the week preceding
             EUS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Topazian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Topazian M, Camilleri M, De La Mora-Levy J, Enders FB, Foxx-Orenstein AE, Levy MJ, Nehra V, Talley NJ. Endoscopic ultrasound-guided gastric botulinum toxin injections in obese subjects: a pilot study. Obes Surg. 2008 Apr;18(4):401-7. doi: 10.1007/s11695-008-9442-x. Epub 2008 Feb 20.</citation>
    <PMID>18286347</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <last_update_submitted>January 2, 2013</last_update_submitted>
  <last_update_submitted_qc>January 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mark Topazian</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Gastric Emptying</keyword>
  <keyword>Satiation</keyword>
  <keyword>Endosonography</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Feeding Behavior</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

